Universität zu Köln

Prattes, Juergen, Wauters, Joost, Giacobbe, Daniele Roberto ORCID: 0000-0003-2385-1759, Salmanton-Garcia, Jon, Maertens, Johan, Bourgeois, Marc, Reynders, Marijke, Rutsaert, Lynn, Van Regenmortel, Niels, Lormans, Piet, Feys, Simon, Reisinger, Alexander Christian, Cornely, Oliver A. ORCID: 0000-0001-9599-3137, Lahmer, Tobias, Valerio, Maricela, Delhaes, Laurence, Jabeen, Kauser, Steinmann, Joerg, Chamula, Mathilde, Bassetti, Matteo, Hatzl, Stefan, Rautemaa-Richardson, Riina, Koehler, Philipp ORCID: 0000-0002-7386-7495, Lagrou, Katrien and Hoenigl, Martin ORCID: 0000-0002-1653-2824 (2022). Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin. Microbiol. Infect., 28 (4). S. 580 - 588. OXFORD: ELSEVIER SCI LTD. ISSN 1469-0691

Full text not available from this repository.

Abstract

Objectives: Coronavirus disease 2019 (COVID-19) -associated pulmonary aspergillosis (CAPA) has emerged as a complication in critically ill COVID-19 patients. The objectives of this multinational study were to determine the prevalence of CAPA in patients with COVID-19 in intensive care units (ICU) and to investigate risk factors for CAPA as well as outcome. Methods: The European Confederation of Medical Mycology (ECMM) conducted a multinational study including 20 centres from nine countries to assess epidemiology, risk factors and outcome of CAPA. CAPA was defined according to the 2020 ECMM/ISHAM consensus definitions. Results: A total of 592 patients were included in this study, including 11 (1.9%) patients with histologically proven CAPA, 80 (13.5%) with probable CAPA, 18 (3%) with possible CAPA and 483 (81.6%) without CAPA. CAPA was diagnosed a median of 8 days (range 0-31 days) after ICU admission predominantly in older patients (adjusted hazard ratio (aHR) 1.04 per year; 95% CI 1.02-1.06) with any form of invasive respiratory support (HR 3.4; 95% CI 1.84-6.25) and receiving tocilizumab (HR 2.45; 95% CI 1.41-4.25). Median prevalence of CAPA per centre was 10.7% (range 1.7%-26.8%). CAPA was associated with significantly lower 90-day ICU survival rate (29% in patients with CAPA versus 57% in patients without CAPA; Mantel-Byar p < 0.001) and remained an independent negative prognostic variable after adjusting for other predictors of survival (HR 2.14; 95% CI 1.59-2.87, p <= 0.001). Conclusion: Prevalence of CAPA varied between centres. CAPA was significantly more prevalent among older patients, patients receiving invasive ventilation and patients receiving tocilizumab, and was an independent strong predictor of ICU mortality. (C) 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Prattes, Juergen UNSPECIFIED UNSPECIFIED UNSPECIFIED Wauters, Joost UNSPECIFIED UNSPECIFIED UNSPECIFIED Giacobbe, Daniele Roberto UNSPECIFIED orcid.org/0000-0003-2385-1759 UNSPECIFIED Salmanton-Garcia, Jon UNSPECIFIED UNSPECIFIED UNSPECIFIED Maertens, Johan UNSPECIFIED UNSPECIFIED UNSPECIFIED Bourgeois, Marc UNSPECIFIED UNSPECIFIED UNSPECIFIED Reynders, Marijke UNSPECIFIED UNSPECIFIED UNSPECIFIED Rutsaert, Lynn UNSPECIFIED UNSPECIFIED UNSPECIFIED Van Regenmortel, Niels UNSPECIFIED UNSPECIFIED UNSPECIFIED Lormans, Piet UNSPECIFIED UNSPECIFIED UNSPECIFIED Feys, Simon UNSPECIFIED UNSPECIFIED UNSPECIFIED Reisinger, Alexander Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Cornely, Oliver A. UNSPECIFIED orcid.org/0000-0001-9599-3137 UNSPECIFIED Lahmer, Tobias UNSPECIFIED UNSPECIFIED UNSPECIFIED Valerio, Maricela UNSPECIFIED UNSPECIFIED UNSPECIFIED Delhaes, Laurence UNSPECIFIED UNSPECIFIED UNSPECIFIED Jabeen, Kauser UNSPECIFIED UNSPECIFIED UNSPECIFIED Steinmann, Joerg UNSPECIFIED UNSPECIFIED UNSPECIFIED Chamula, Mathilde UNSPECIFIED UNSPECIFIED UNSPECIFIED Bassetti, Matteo UNSPECIFIED UNSPECIFIED UNSPECIFIED Hatzl, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Rautemaa-Richardson, Riina UNSPECIFIED UNSPECIFIED UNSPECIFIED Koehler, Philipp UNSPECIFIED orcid.org/0000-0002-7386-7495 UNSPECIFIED Lagrou, Katrien UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoenigl, Martin UNSPECIFIED orcid.org/0000-0002-1653-2824 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-695697
DOI:	10.1016/j.cmi.2021.08.014
Journal or Publication Title:	Clin. Microbiol. Infect.
Volume:	28
Number:	4
Page Range:	S. 580 - 588
Date:	2022
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	1469-0691
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INVASIVE FUNGAL DISEASE Multiple languages Infectious Diseases; Microbiology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69569